Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

DaVita (DVA) stock in plain English

Free brief · no signupStart here
DVAPublished Nov 16, 2026
DaVita Inc
Healthcare · Medical Care Facilities
Delivers kidney dialysis services and related lab testing across outpatient clinics and patient homes.
Assets:
3,269 outpatient clinicsFacilities located across the United States and selected international markets
65,000 team membersNephrology nurses, technicians, and specialized clinical care coordinators
Home dialysis networkEquipment support and remote monitoring for peritoneal dialysis patients
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

70
OPS ScoreOperating finances
Latest quote
-3.37%$156.34
$9.83B
11.8×
$14.25B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was DVA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does DaVita (DVA) do?

DaVita Inc (DVA) is a U.S.-listed company in Healthcare (Medical Care Facilities). What it does: Delivers kidney dialysis services and related lab testing across outpatient clinics and patient homes. Operates thousands of outpatient clinics providing specialized dialysis care to patients with chronic kidney failure. It is worth $9.83B on the market and sold $14.25B over the last year.

Market cap
$9.83B
P/E ratio
11.8×
Annual sales
$14.25B
Sector
Healthcare
Industry
Medical Care Facilities
Brief updated
Nov 16, 2026

DVA’s flags, in plain English

Each flag is a number from DaVita’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Growth vs Price

The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.

Cheap on Cash Flow

Priced at 7.6 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Earnings Jumping

Profits up 37.6% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.

Growth Cooling

Sales growth slowed to 3.4% a year over 5 years. Sales are growing more slowly than before, which makes the current share price harder to justify.

1 more green flag open with the free trial. Try it free for 7 days.

Questions about DVA

How big is DaVita?

DaVita’s market cap is $9.83B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $14.25B: what customers paid the company over the last year, before any costs.

What is DVA’s P/E ratio?

DVA’s P/E ratio is 11.8×. Investors pay about 11.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with DVA?

Federal Medicare reimbursement rate limits directly restrict revenue growth while clinical labor wages remain elevated. That is one risk on DaVita’s card. Its first risk flag is Growth Cooling, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From DaVita’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. DVA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card